logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9963444 B1

PDFFull Text
Date of Patent:
May. 08, 2018

Filed:

May. 13, 2015

N-acylethanolamine hydrolyzing acid amidase (naaa) inhibitors and their use thereof

Applicant:

Northeastern University, Boston, MA (US);

Inventors:

Michael Malamas, Boston, MA (US);

Alexandros Makriyannis, Boston, MA (US);

Kumara Vadivel Subramanian, Boston, MA (US);

Kyle M. Whitten, Boston, MA (US);

Nikolai M. Zvonok, Boston, MA (US);

Jay Matthew West, Boston, MA (US);

Michael Mccormack, Boston, MA (US);

Spiro Pavlopoulos, Boston, MA (US);

Assignee:

Northeastern University, Boston, MA (US);

Attorney:

Hamilton, Brook, Smith & Reynolds, P.C.

Primary Examiner:

Kahsay Habte

Int. Cl.
CPC ...
C07C 255/46 (2006.01); C07D 405/12 (2006.01); C07D 403/12 (2006.01); C07D 317/54 (2006.01); C07D 319/18 (2006.01); C07D 231/12 (2006.01); C07D 401/12 (2006.01); C07D 413/12 (2006.01); C07D 261/08 (2006.01); C07D 205/04 (2006.01); C07D 207/12 (2006.01); C07D 211/10 (2006.01); C07D 211/26 (2006.01); C07D 211/46 (2006.01); C07D 213/46 (2006.01); C07D 213/64 (2006.01); C07C 331/20 (2006.01); C07C 331/24 (2006.01); C07C 331/26 (2006.01); C07D 213/30 (2006.01); C07D 213/36 (2006.01); C07D 239/26 (2006.01); C07D 239/28 (2006.01); C07D 241/18 (2006.01); C07D 295/13 (2006.01); C07D 295/135 (2006.01); C07D 317/58 (2006.01);
U.S. Cl.
CPC ...
C07D 405/12 (2013.01); C07C 255/46 (2013.01); C07C 331/20 (2013.01); C07C 331/24 (2013.01); C07C 331/26 (2013.01); C07D 205/04 (2013.01); C07D 207/12 (2013.01); C07D 211/10 (2013.01); C07D 211/26 (2013.01); C07D 211/46 (2013.01); C07D 213/30 (2013.01); C07D 213/36 (2013.01); C07D 213/46 (2013.01); C07D 213/64 (2013.01); C07D 231/12 (2013.01); C07D 239/26 (2013.01); C07D 239/28 (2013.01); C07D 241/18 (2013.01); C07D 261/08 (2013.01); C07D 295/13 (2013.01); C07D 295/135 (2013.01); C07D 317/54 (2013.01); C07D 317/58 (2013.01); C07D 319/18 (2013.01); C07D 401/12 (2013.01); C07D 403/12 (2013.01); C07D 413/12 (2013.01); C07B 2200/07 (2013.01); C07C 2601/04 (2017.05); C07C 2601/08 (2017.05); C07C 2601/14 (2017.05); C07C 2602/08 (2017.05);
Abstract

A compound is represented as Formula I, a tautomer thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. Compounds of Formula I are inhibitors of N-acylethanolamine hydrolyzing acid amidase (NAAA). The present technology is directed to compounds, compositions, and methods to inhibit N-acylethanolamine hydrolyzing acid amidase and to treat N-acylethanolamine hydrolyzing acid amidase mediated conditions in a subject.

Find Patent Forward Citations

Loading…